Skip to content

Esophageal Hypersensitivity Study in Healthy Volunteers

A Phase I, Two Centre, Double-blind, Randomized, Cross-over Study to Evaluate AZD1386 in Single Doses of 30 mg and 95 mg Compared to Placebo in a Multimodal Experimental Pain Model on Esophageal Sensitivity and Development of Sensitization in Healthy Male Volunteers

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00711048
Enrollment
45
Registered
2008-07-08
Start date
2008-06-30
Completion date
2009-07-31
Last updated
2009-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Sensitivity, Pain

Keywords

GERD, healthy volunteer, esophagus, pain

Brief summary

The purpose of the study is to compare sensitivity and sensitization of visceral pain in the esophagus using different pain stimuli

Interventions

oral, single dose

DRUGPlacebo

Oral solution, single dose

Sponsors

AstraZeneca
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
20 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Provision of written consent * Clinically normal physical findings * Sensitization potential

Exclusion criteria

* Clinically significant illness within 2 weeks prior to the first dose of investigational product * History of clinically significant disease * Use of prescribed medication during the 2 weeks before administration of the first dose of investigational product

Design outcomes

Primary

MeasureTime frame
VAS scale and clockSeveral occasions during the study days

Secondary

MeasureTime frame
VAS scale and pressure, VAS scale and current, VAS scale and acid volumeSeveral occasions during the study days
Pharmacokinetic variablesSeveral occasions during the study days
Safety variables (adverse events, blood pressure, safety lab, ECG and body temperature)Several occasions during the study days

Countries

Denmark, Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026